NR1H4 and liver disorder: We acknowledge that our study cannot elucidate the exact molecular mechanisms disrupting the gut–liver FXR-FGF19 signaling axis in ACLD, but importantly, our results clearly call for a critical assessment of FXR-FGF19-related interventions in the specific setting of ACLD—while therapeutic studies are ongoing in patients with liver disease [28].